{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:50:03Z","timestamp":1792450203991,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors, notably PD-1\/PD-L1 monoclonal antibodies, are now used as first-line treatments for hepatocellular carcinoma (HCC) and have improved outcomes for some patients. Nevertheless, their response rate remains below 30%, largely due to HCC\u2019s immunosuppressive microenvironment and insufficient T-cell infiltration. Strategies to address these limitations are urgently needed. Ion homeostasis has been recognized as a pivotal factor in modulating the tumor immune microenvironment. This study found that the expression and functionality of CFTR, a chloride channel, in human HCC tissues and cells were negatively correlated with HCC progression. Furthermore, it was utilized human\/murine HCC cell lines, mouse models, and human HCC organoids to investigate how CFTR activation (genetic\/pharmacological) impacts HCC biology. Key assessments included: (1) tumor cell ion homeostasis, (2) downstream signaling proteins, (3) tumor microenvironment cytokine levels, and (4) functional changes in TAMs, CD8\u2009+\u2009T cells, and Tregs. We further assessed combined effects with PD-L1 antibodies to explore CFTR-immune checkpoint interplay, providing multidimensional insights into CFTR-mediated HCC pathogenesis and immunomodulation. The results showed that upregulation of CFTR expression and channel activity reduced intracellular Cl\u207b and Ca\u00b2\u207a concentrations in HCC cells, thereby suppressing the expression of chloride-associated transcription factor RUNX1 and calcium pathway transcription factor NF-\u03baB. This regulatory mechanism orchestrates the synthesis and secretion of cytokines\/chemokines (CSF-1, TGF-\u03b2, CCL20, CCL22), driving macrophage polarization toward M1 phenotype while promoting M1 macrophage and CD8\u2009+\u2009T lymphocyte infiltration. Concurrently, it suppressed Treg proliferation and tumor infiltration. These immunomodulatory effects synergistically enhanced PD-1\/PD-L1 immune checkpoint blockade efficacy, ultimately augmenting therapeutic outcomes in HCC. Therefore, this study establishes CFTR potentiation as a novel immunomodulatory axis, proposing biomarker-driven combination regimens to enhance therapeutic efficacy while mitigating immune-related adverse events, thereby addressing an urgent unmet need in translational hepatology.<\/jats:p>","DOI":"10.1038\/s41419-026-08907-7","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:06:30Z","timestamp":1781100390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CFTR-driven immune microenvironment reprogramming synergizes with anti-PD-L1 antibody in hepatocellular carcinoma"],"prefix":"10.1038","volume":"17","author":[{"given":"Yijia","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6723-0957","authenticated-orcid":false,"given":"Mingyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"8907_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1586\/egh.09.35","volume":"3","author":"MI Shariff","year":"2009","unstructured":"Shariff MI, et al. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2009;3:353\u201367.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"8907_CR2","first-page":"8","volume":"3","author":"AS Yu","year":"2003","unstructured":"Yu AS, Keeffe EB. Management of hepatocellular carcinomal. Rev Gastroenterol Disord. 2003;3:8\u201324.","journal-title":"Rev Gastroenterol Disord"},{"key":"8907_CR3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cell.2020.11.041","volume":"184","author":"Y Sun","year":"2021","unstructured":"Sun Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021;184:404\u201321.","journal-title":"Cell"},{"key":"8907_CR4","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1189\/jlb.0406249","volume":"80","author":"JP Edwards","year":"2006","unstructured":"Edwards JP, et al. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol. 2006;80:1298\u2013307.","journal-title":"J Leukoc Biol"},{"key":"8907_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1152\/physrev.00044.2016","volume":"98","author":"N Prevarskaya","year":"2018","unstructured":"Prevarskaya N, Skryma R, Shuba Y. Ion channels in cancer: are cancer hallmarks oncochannelopathies? Physiol Rev. 2018;98:559\u2013621.","journal-title":"Physiol Rev"},{"key":"8907_CR6","doi-asserted-by":"crossref","unstructured":"Capatina, AL, Lagos, D, Brackenbury, WJ. Targeting ion channels for cancer treatment: current progress and future challenges. Rev. Physiol. Biochem. Pharmacol. 2020;183:1\u201343.","DOI":"10.1007\/112_2020_46"},{"key":"8907_CR7","doi-asserted-by":"publisher","first-page":"6490","DOI":"10.1038\/onc.2017.234","volume":"36","author":"AA Peters","year":"2017","unstructured":"Peters AA, et al. Oncosis and apoptosis induction by activation of an overexpressed ion channel in breast cancer cells. Oncogene. 2017;36:6490\u2013500.","journal-title":"Oncogene"},{"key":"8907_CR8","doi-asserted-by":"publisher","first-page":"a009498","DOI":"10.1101\/cshperspect.a009498","volume":"3","author":"TC Hwang","year":"2013","unstructured":"Hwang TC, Kirk KL. The CFTR ion channel: gating, regulation, and anion permeation. Cold Spring Harb Perspect Med. 2013;3:a009498.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"8907_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.711593","volume":"12","author":"LH Jiang","year":"2021","unstructured":"Jiang LH, et al. Editorial: ion channel signalling in cancer: from molecular mechanisms to therapeutics. Front Pharm. 2021;12:711593.","journal-title":"Front Pharm"},{"key":"8907_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/112_2020_28","volume":"183","author":"A Ram\u00edrez","year":"2022","unstructured":"Ram\u00edrez A, et al. Novel therapeutic approaches of ion channels and transporters in cancer. Rev Physiol Biochem Pharm. 2022;183:45\u2013101.","journal-title":"Rev Physiol Biochem Pharm"},{"key":"8907_CR11","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/s41417-024-00782-8","volume":"31","author":"L Zhang","year":"2024","unstructured":"Zhang L, et al. Pathophysiological role of ion channels and transporters in hepatocellular carcinoma. Cancer Gene Ther. 2024;31:1611\u20138.","journal-title":"Cancer Gene Ther"},{"key":"8907_CR12","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/j.1440-1843.2011.01994.x","volume":"16","author":"JW Son","year":"2011","unstructured":"Son JW, et al. Promoter hypermethylation of the CFTR gene and clinical pathological features associated with non-small cell lung cancer. Respirology. 2011;16:1203\u20139.","journal-title":"Respirology"},{"key":"8907_CR13","doi-asserted-by":"publisher","first-page":"20130108","DOI":"10.1098\/rstb.2013.0108","volume":"369","author":"F Lang","year":"2014","unstructured":"Lang F, Stournaras C. Ion channels in cancer: future perspectives and clinical potential. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130108.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"8907_CR14","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1113\/jphysiol.2008.164970","volume":"587","author":"HC Chan","year":"2009","unstructured":"Chan HC, et al. The cystic fibrosis transmembrane conductance regulator in reproductive health and disease. Physiol. 2009;587:2187\u201395.","journal-title":"Physiol"},{"key":"8907_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1042\/BST0370863","volume":"37","author":"PJ Buchanan","year":"2009","unstructured":"Buchanan PJ, et al. Role of CFTR, Pseudomonas aeruginosa and Toll-like receptors in cystic fibrosis lung inflammation. Biochem Soc Trans. 2009;37:863\u20137.","journal-title":"Biochem Soc Trans"},{"key":"8907_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.7150\/thno.103384","volume":"15","author":"Q Shi","year":"2025","unstructured":"Shi Q, et al. Targeting ion channels: innovative approaches to combat cancer drug resistance. Theranostics. 2025;15:521\u201345.","journal-title":"Theranostics"},{"key":"8907_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.71360","volume":"60","author":"T Shugg","year":"2025","unstructured":"Shugg T, et al. Enrichment of germline cystic fibrosis transmembrane conductance regulator (CFTR) pathogenic variants in patients with solid tumors: evidence for increased cancer risk. Pediatr Pulmonol. 2025;60:e71360.","journal-title":"Pediatr Pulmonol"},{"key":"8907_CR18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1126\/science.abg5784","volume":"373","author":"TD Martin","year":"2021","unstructured":"Martin TD, et al. The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation. Science. 2021;373:1327\u201335.","journal-title":"Science"},{"key":"8907_CR19","doi-asserted-by":"publisher","first-page":"E2086","DOI":"10.1073\/pnas.1613546114","volume":"114","author":"Z Bozoky","year":"2017","unstructured":"Bozoky Z, et al. Synergy of cAMP and calcium signaling pathways in CFTR regulation. Proc Natl Acad Sci USA 2017;114:E2086\u201395.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8907_CR20","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.bbrc.2018.12.080","volume":"508","author":"X Zhong","year":"2019","unstructured":"Zhong X, et al. CFTR activation suppresses glioblastoma cell proliferation, migration and invasion. Biochem Biophys Res Commun. 2019;508:1279\u201385.","journal-title":"Biochem Biophys Res Commun"},{"key":"8907_CR21","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00424-016-1830-9","volume":"468","author":"JA Contreras-Vite","year":"2016","unstructured":"Contreras-Vite JA, et al. Revealing the activation pathway for TMEM16A chloride channels from macroscopic currents and kinetic models. Pflug Arch. 2016;468:1241\u201357.","journal-title":"Pflug Arch"},{"key":"8907_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/1097-4644(20010401)81:1<93::AID-JCB1026>3.0.CO;2-I","volume":"81","author":"JA Kim","year":"2001","unstructured":"Kim JA, et al. Role of pertussis toxin-sensitive G-proteins in intracellular Ca2+ release and apoptosis induced by inhibiting cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channels in HepG2 human hepatoblastoma cells. J Cell Biochem. 2001;81:93\u2013101.","journal-title":"J Cell Biochem"},{"key":"8907_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3431597","volume":"2020","author":"J Hao","year":"2020","unstructured":"Hao J, et al. The crosstalk between calcium ions and aldosterone contributes to inflammation, apoptosis, and calcification of VSMC via the AIF-1\/NF-\u03baB pathway in uremia. Oxid Med Cell Longev. 2020;2020:3431597.","journal-title":"Oxid Med Cell Longev"},{"key":"8907_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7295224","volume":"2022","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, et al. Regulation of Cr(VI)-induced premature senescence in L02 hepatocytes by ROS-Ca2+-NF-\u03baB signaling. Oxid Med Cell Longev. 2022;2022:7295224.","journal-title":"Oxid Med Cell Longev"},{"key":"8907_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","volume":"12","author":"Y Lin","year":"2019","unstructured":"Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol. 2019;12:76.","journal-title":"J Hematol Oncol"},{"key":"8907_CR26","doi-asserted-by":"publisher","first-page":"5242","DOI":"10.1158\/0008-5472.CAN-05-4463","volume":"66","author":"O Vasiljeva","year":"2006","unstructured":"Vasiljeva O, et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 2006;66:5242\u201350.","journal-title":"Cancer Res"},{"key":"8907_CR27","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1093\/carcin\/bgh146","volume":"25","author":"T Hagemann","year":"2004","unstructured":"Hagemann T, et al. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis. 2004;25:1543\u20139.","journal-title":"Carcinogenesis"},{"key":"8907_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrc1098","volume":"3","author":"IJ Fidler","year":"2003","unstructured":"Fidler IJ. The pathogenesis of cancer metastasis: the \u2018seed and soil\u2019 hypothesis revisited. Nat Rev Cancer. 2003;3:453\u20138.","journal-title":"Nat Rev Cancer"},{"key":"8907_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701924","volume":"12","author":"S Korinfskaya","year":"2021","unstructured":"Korinfskaya S, et al. Runx transcription factors in T cells-what is beyond thymic development? Front Immunol. 2021;12:701924.","journal-title":"Front Immunol"},{"key":"8907_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41413-022-00231-y","volume":"10","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, et al. Runx1 is a key regulator of articular cartilage homeostasis by orchestrating YAP, TGF\u03b2, and Wnt signaling in articular cartilage formation and osteoarthritis. Bone Res. 2022;10:63.","journal-title":"Bone Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08907-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08907-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08907-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:03:16Z","timestamp":1786971796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08907-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8907"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08907-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal protocols and experiments were approved by the Committee on the Ethics of Animal Experiments of the Shenyang Pharmaceutical University (SYPU-IACUC-C2021-9-30-102) or the Center for Model Biology Research of Saiye (TCM220719JX1). Ethical approval of HCC patients was obtained from the Institutional Review Board of Shengjing Hospital (2022PS1101K).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors approved the final version.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All study participants provided written informed consent to the study.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"731"}}